Open AccessPossible Mechanisms of Drugs Used in the Treatment of COVID-19: A Pharmacological Perspective
Author(s) -
Ravindra Babu Pingili,
Tanvija Kodali,
Naveen Babu Kilaru,
Vijaya R. Dirisala,
Siva Reddy Challa,
Akhila Kondru,
Sirisha Koppula,
Sravani Melike,
Vyshnavi Toleti,
Vara Prasad Saka
Publication year - 2022
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2022/v34i1b35352
Subject(s) - tocilizumab , coronavirus , virology , medicine , coronaviridae , rhinovirus , chloroquine , common cold , favipiravir , nitazoxanide , hydroxychloroquine , azithromycin , virus , immunology , covid-19 , biology , rheumatoid arthritis , disease , malaria , infectious disease (medical specialty) , microbiology and biotechnology , antibiotics
Coronaviruses are a type of virus that can infect both animals and humans. Coronaviruses are divided into thirty-nine species and twenty-seven subgenus in the family Coronaviridae, according to the current classification. Seven of these are known to induce respiratory infections, while four others can cause cold-like symptoms on a regular basis. SARS CoV, MERS-CoV, and SARS CoV-2 infection are three examples of viral rebound. They are to blame for SARS, MERS, and the most recent Coronavirus epidemic discovered in 2019. (COVID-19). The World Health Organization declared the respiratory sickness caused by the SARS-CoV-2 infection to be a pandemic (WHO). For this COVID-19, there are currently no properly shown managements. The virology of SARS-CoV-2 has yielded a large number of therapeutic targets. Remdesivir appears to be the most promising treatment. Currently, COVID-19 is treated with Dexamethasone, Tocilizumab, Remdesivir, Chloroquine and Hydroxychloroquine, Lopinavir, Favipiravir, Niclosamide, Azithromycin, Sarilumab, Baricitinib, Ruxolitinib, Ribavarin, Nitazoxanide, Umifenovir, Camostat, Ciclesonide, Darun They exert their effects through blocking receptors such as IL 6, TMPRSS2, CD147, and AAKI, as well as RNA dependent RNA polymerase, membrane fusion, endocytosis, and proteolysis. The authors of this study looked at the available literature on the SARS-CoV-2 virus and the COVID-19 virus in terms of therapeutic evidence. This in-depth and thorough examination provides an excellent overview of the most up-to-date information on the medications used to treat COVID-19.